Authorities in China have allowed a US export control officer to inspect a facility run by Wuxi Biologics, a firm that makes ingredients for AstraZeneca’s Covid-19 vaccine.
News of the inspection, which could help Wuxi Biologics get taken off a US trade blacklist, caused the company’s shares to jump as much as 12% on Tuesday.
A US Commerce Department official revealed that the export control officer was allowed to inspect a company in the city of Wuxi, near Shanghai, in eastern China last week.
The official declined to identify the company or companies involved, but a person familiar with the matter said a check was conducted last week at Wuxi Biologics.
If the US deems the check favourable, it could be removed from the list.
The company did not respond to requests for a comment. Shares in Wuxi Biologics hit their highest since January 24, before ending more than 6.5% up when the market closed in Hong Kong.
Wuxi Biologics units in Wuxi and Shanghai were among 33 entities added to the US Commerce Department’s “Unverified List” in February. The company was one of only two added to the list with addresses in Wuxi.
The United States placed the entities on the list because it could not conduct on-site inspections to verify information related to them and US items shipped to them.
The resumption of inspections is seen by the United States as a positive development amid increased tensions with China over a range of issues, including the US blocking of imports linked to forced labour in China and the possible delisting of Chinese companies that don’t meet audit requirements.
Last week, there also were renewed threats to shut down SMIC, China’s top chipmaker, if it is found to be supplying Russia in violation of US export controls.
“I do have some good news,” the Commerce Department official, who could not be identified publicly, told a conference on export controls in Washington on Thursday.
“We were able to get some end-use check movement this week in Wuxi.”
The official added that hopefully a US export control officer would be able to go into another province, Anhui, in the coming weeks, though that could be delayed by fresh Covid-19 outbreaks.
US inspections of Chinese companies require approval and scheduling by China’s commerce ministry, the official said.
China’s zero tolerance Covid-19 protocols account for most of the delay over the last couple of years, though there were some opportunities to have conducted checks, the official said.
“Covid aside, it’s really dependent on them to agree to schedule the pending end-use checks that we have,” the official said.
China’s Commerce ministry did not respond to a request for comment.
‘Importance of End-Use Checks’
In February, US Assistant Commerce Secretary Matthew Axelod said the additions to the list “signal to the PRC government the importance of their cooperation in scheduling end-use checks.”
But China’s Ministry of Commerce slammed the development and said Washington should correct its “wrongdoings,” return to the track of cooperation and contribute more to the global economic recovery.
During an investor day on June 16, Wuxi Biologics said that it hoped to see the “unverified list” issue resolved for at least one of its units by September, and for the other by the end of the year.
The company said it had initially expected an inspection in April, which was disrupted by Covid-19. It said it had not seen a significant impact on actual operations from being added to the list.
US exporters can engage with parties on the unverified list, but are required to conduct additional due diligence before they can ship goods to them, and may need to apply for more licences.
Citi analysts said in a report on Tuesday that the company’s management had noted the result of the checks could be positive but that they were still waiting for final confirmation.
“In our view, the potential removal of Wuxi site from the [unverified list] would help alleviate market concerns on geopolitical risk and boost market sentiment on the CRO [contract research organisation] sector,” they said.
- Reuters with additional editing by Jim Pollard